Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 359

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 359
---
 the Company’s capital

Personnel expenses other than share-based compensation

The line item amounted to € 22,354 21,708 22,148 175 177

Depreciation and amortization

The line item is mainly composed of the amortization of the monalizumab, IPH5201 intangible assets (see Note 6).

Cost of supplies and consumable materials

Cost of supplies and consumable materials consists mainly of the cost of procurement of the Company’s drug substance and/or drug product that is manufactured by third-parties. This line item amounts to €3,582thousand €2,855thousand and €3,056thousand for the years ended December 31, 2022, 2023 and 2024, respectively.

F-80

15)Net financial income (loss)

Net financial income (loss) can be analyzed as follows:

                                               Year ended December 31,                                                               
  (in thousands of euro)                                          2022                 2023                         2024             
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Interests and gains on financial assets                          546                               3,177                    2,437  
  Unrealized gains on financials assets                            418                               1,648                    1,983  
  Foreign exchange gains                                                    3,810                    2,109                    1,658  
  Other financial income                                             —                 —                                             
  Financial income                                                          4,775                    6,934                    6,079  
  Foreign exchange losses                                     ( 2,983)                 ( 1,195)                 ( 3,409)             
  Unrealized losses on financial assets                       ( 2,050)                 —                                             
  Interest on financial liabilities                             ( 288)                 ( 640)                     ( 566)             
  Other financial expenses                                           —                 —                                             
  Financial expenses                                          ( 5,321)                 ( 1,835)                 ( 3,975)             
  Net financial income (loss)                                   ( 546)                               5,099                    2,104  

For the financial years ended December 31, 2023 and 2024, the foreign exchange gains and losses mainly result from the variance of the exchange rate between the Euro and the U. S. dollar on U. S. dollars denominated collaboration liabilities, and cash and cash equivalent and financial assets accounts